Form 4: ResMed CEO Michael Farrell Executes Stock Transactions Under 10b5-1 Plan
SEC Form 4 Filing
ResMed's CEO, Michael Farrell, engaged in multiple stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.
Summary
- ResMed CEO Michael Farrell executed several transactions involving ResMed common stock.
- These transactions included the acquisition of 14,683 shares through option exercises at $84.98 per share and the sale of 14,683 shares at a weighted average price of $246.259 per share.
- Additional transactions involved the disposition of shares to cover tax obligations related to the vesting of restricted stock units.
- These transactions were conducted under a Rule 10b5-1 plan adopted on January 31, 2024.
- The reported transactions resulted in a change in Mr. Farrell's direct holdings of ResMed common stock.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock transactions by an executive, which is neither positive nor negative in itself. The use of a 10b5-1 plan suggests a planned and expected activity.
Industry Context
This filing is a routine disclosure of insider trading activity and is common for executives of publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, such as those in the medical device industry like Medtronic or Stryker.
- These plans allow executives to sell shares at predetermined times and prices, mitigating the risk of insider trading allegations.
- The reported transactions are consistent with typical executive compensation practices, which often include stock options and restricted stock units.
Stakeholder Impact
- The transactions may have a minor impact on the stock price due to the volume of shares traded.
- The transactions are part of the executive's compensation and do not indicate any change in the company's performance or outlook.
Key Dates
| Date | Description |
|---|---|
| 01/31/2024 | Date the Rule 10b5-1 plan was adopted. |
| 10/31/2024 | Date of ResMed stock purchase through the Employee Stock Purchase Plan. |
| 11/07/2024 | Date of option exercise and stock sale. |
| 11/11/2024 | Date of tax withholding transactions. |
| 11/12/2024 | Date of signature on the Form 4. |
| 11/16/2024 | Expiration date of the options. |
Keywords
ResMed, Michael Farrell, stock transactions, Form 4, 10b5-1 plan, insider trading, stock options, restricted stock units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.